At-Risk
FDA Expands Approval of GSK’s RSV Vaccine to Include At-Risk Adults Aged 50-59
RSV vaccine, GSK, FDA approval, at-risk adults, respiratory syncytial virus, Arexvy
Actionable Insights Powered by AI
RSV vaccine, GSK, FDA approval, at-risk adults, respiratory syncytial virus, Arexvy